NZ548897A - Methods of modulating IL-23 activity; related reagents - Google Patents
Methods of modulating IL-23 activity; related reagentsInfo
- Publication number
- NZ548897A NZ548897A NZ548897A NZ54889705A NZ548897A NZ 548897 A NZ548897 A NZ 548897A NZ 548897 A NZ548897 A NZ 548897A NZ 54889705 A NZ54889705 A NZ 54889705A NZ 548897 A NZ548897 A NZ 548897A
- Authority
- NZ
- New Zealand
- Prior art keywords
- modulating
- activity
- methods
- related reagents
- specifically binds
- Prior art date
Links
- 102000013264 Interleukin-23 Human genes 0.000 title abstract 4
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 abstract 4
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 abstract 4
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000005867 T cell response Effects 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54570804P | 2004-02-17 | 2004-02-17 | |
| PCT/US2005/004742 WO2005079837A1 (en) | 2004-02-17 | 2005-02-15 | Methods of modulating il-23 activity; related reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ548897A true NZ548897A (en) | 2009-07-31 |
Family
ID=34886185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ548897A NZ548897A (en) | 2004-02-17 | 2005-02-15 | Methods of modulating IL-23 activity; related reagents |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8263080B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1901768B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4903061B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1942201B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE533502T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005215527B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0507794A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2556425A1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20064194L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ548897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005079837A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200606620B (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| NZ539271A (en) * | 2002-10-30 | 2008-12-24 | Genentech Inc | Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23) |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1937721T1 (sl) * | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| JP2009540018A (ja) * | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
| TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
| CA2679381A1 (en) * | 2007-02-28 | 2008-09-04 | Schering Corporation | Engineered anti-il-23r antibodies |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
| EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
| EP2480251B1 (en) * | 2009-09-21 | 2025-12-03 | Peptinov | Carrier conjugates of il-23-peptides and their induced antibodies |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23 항체 |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN103837687A (zh) * | 2014-03-10 | 2014-06-04 | 青岛康立泰药业有限公司 | 使用具有白细胞介素-12受体的细胞检测重组人白细胞介素-12体外活性的方法及应用 |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| KR20170120616A (ko) | 2015-02-04 | 2017-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| KR101873499B1 (ko) * | 2015-02-10 | 2018-07-03 | 주식회사 원메디칼 | 혈관 질환 진단용 바이오 마커 및 이의 용도 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| EP3634465A4 (en) * | 2017-05-25 | 2021-01-20 | The Broad Institute, Inc. | LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF |
| US20200147177A1 (en) * | 2017-07-17 | 2020-05-14 | Chu De Nantes - Centre Hospitalier Universitaire De Nantes | Interleukin 12 (il12) or derivative thereof for use in the treatment of secondary disease |
| JP7516250B2 (ja) | 2018-03-05 | 2024-07-16 | ヤンセン バイオテツク,インコーポレーテツド | 抗il-23特異的抗体を用いたクローン病の治療方法 |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体および抗pd-1抗体の共-製剤 |
| MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| US6756481B2 (en) * | 2000-05-10 | 2004-06-29 | Schering Corporation | IL-23 receptor binding compositions |
| US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| WO2003092610A2 (en) * | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
| NZ539271A (en) * | 2002-10-30 | 2008-12-24 | Genentech Inc | Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23) |
| AU2003303384A1 (en) * | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| CA2511838C (en) * | 2002-12-31 | 2014-05-06 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| ATE440864T1 (de) * | 2003-03-10 | 2009-09-15 | Schering Corp | Verwendung von il-23-antagonisten; verwandte reagenzien |
| US7582297B2 (en) * | 2003-04-11 | 2009-09-01 | Medimmune, Llc | Methods of treating respiratory conditions |
| EP1623011B1 (en) * | 2003-05-09 | 2013-01-02 | Janssen Biotech, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
-
2005
- 2005-02-15 CN CN2005800114552A patent/CN1942201B/zh not_active Expired - Fee Related
- 2005-02-15 AU AU2005215527A patent/AU2005215527B2/en not_active Ceased
- 2005-02-15 JP JP2006553341A patent/JP4903061B2/ja not_active Expired - Fee Related
- 2005-02-15 WO PCT/US2005/004742 patent/WO2005079837A1/en not_active Ceased
- 2005-02-15 CA CA002556425A patent/CA2556425A1/en not_active Abandoned
- 2005-02-15 BR BRPI0507794-0A patent/BRPI0507794A/pt not_active IP Right Cessation
- 2005-02-15 AT AT05713576T patent/ATE533502T1/de active
- 2005-02-15 EP EP05713576A patent/EP1901768B1/en not_active Expired - Lifetime
- 2005-02-15 NZ NZ548897A patent/NZ548897A/xx not_active IP Right Cessation
- 2005-02-15 US US11/059,114 patent/US8263080B2/en not_active Expired - Lifetime
-
2006
- 2006-08-08 ZA ZA200606620A patent/ZA200606620B/xx unknown
- 2006-09-15 NO NO20064194A patent/NO20064194L/no not_active Application Discontinuation
-
2011
- 2011-11-30 JP JP2011261668A patent/JP2012092117A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005079837A1 (en) | 2005-09-01 |
| CN1942201B (zh) | 2012-06-20 |
| US8263080B2 (en) | 2012-09-11 |
| JP4903061B2 (ja) | 2012-03-21 |
| BRPI0507794A (pt) | 2007-07-17 |
| JP2007523088A (ja) | 2007-08-16 |
| ZA200606620B (en) | 2008-02-27 |
| NO20064194L (no) | 2006-11-16 |
| CN1942201A (zh) | 2007-04-04 |
| AU2005215527A1 (en) | 2005-09-01 |
| EP1901768A1 (en) | 2008-03-26 |
| EP1901768B1 (en) | 2011-11-16 |
| JP2012092117A (ja) | 2012-05-17 |
| US20050208052A1 (en) | 2005-09-22 |
| ATE533502T1 (de) | 2011-12-15 |
| AU2005215527B2 (en) | 2011-04-07 |
| CA2556425A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Honda-Okubo et al. | Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology | |
| ZA202100676B (en) | Anti-tigit antibody and uses thereof | |
| BRPI0821777B8 (pt) | anticorpo biespecífico bivalente, método para a preparação do mesmo e composição | |
| UA100682C2 (ru) | АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ | |
| MY162752A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| WO2010010467A3 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| NZ602220A (en) | Antibodies with ph dependent antigen binding | |
| MA42530B1 (fr) | Constructions d'anticorps bispécifiques se liant à dll3 et à cd3 | |
| MX359903B (es) | Proteínas estructurales de una mutación del parvovirus como vacunas. | |
| EA201170323A1 (ru) | Антитела против il-12/il-23 | |
| MX2018013008A (es) | Anticuerpos st-2 humanos solubles y ensayos. | |
| WO2006007207A3 (en) | Methods and devices for nucleic acid sequence determination | |
| DE602004031017D1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| TW200611911A (en) | Antibodies to erythropoietin receptor and uses thereof | |
| PH12022551580A1 (en) | Anti-ctla-4 antibody and use thereof | |
| AU2009260320A8 (en) | Antibodies to IL-6 and their uses | |
| UA99339C2 (ru) | Антитело, которое специфично связывает человеческий tyrp1 | |
| Jiang et al. | A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge | |
| UA95329C2 (ru) | Собачий тимусный стромальный лимфопоэтин и его применение | |
| WO2008005880A3 (en) | Antibodies for norovirus | |
| WO2007044033A3 (en) | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen | |
| DK1649051T3 (da) | Bestemmelse af sekvensen for et polynukleotid | |
| WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
| ZA200606620B (en) | Methods of modulating IL-23 activity ; related reagents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: SCHERING CORPORATION, US Free format text: OLD OWNER(S): SCHERING CORPORATION |
|
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |